Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imifoplatin - Promontory Therapeutics

Next Previous
Drug Profile

Imifoplatin - Promontory Therapeutics

Alternative Names: Phosphaplatin PT-112; PT-112

Latest Information Update: 13 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ohio University
  • Developer EMD Serono; National Cancer Institute (USA); National Cheng Kung University; Pfizer; Promontory Therapeutics; SciClone Pharmaceuticals
  • Class Antineoplastics; Cyclohexanes; Diamines; Phosphoric acid esters; Platinum complexes; Small molecules
  • Mechanism of Action Apoprotein stimulants; Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Thymoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant thymoma; Non-small cell lung cancer; Prostate cancer; Thymic epithelial tumour; Thymoma
  • Phase I/II Liver cancer; Solid tumours
  • No development reported Multiple myeloma

Most Recent Events

  • 08 Mar 2024 Promontory Therapeutics plans for a Type C meeting with the FDA in the second half of 2024
  • 08 Mar 2024 Promontory Therapeutics plans for end-of-Phase II meeting with FDA and further engagement with European regulatory authorities
  • 08 Mar 2024 Promontory Therapeutics completes enrolment in the phase I/II trial for Prostate cancer (Late-stage disease, Metastatic disease, Harmone refractory, Second-line therapy or greater) in USA and France (IV) (NCT02266745)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top